Obagi Medical Products Introduces New Clinical Data Showing Combination of Hydroquinone Skin Care System and Tretinoin May Reduce Melasma Severity

Obagi Medical Products, Inc. OMPI announced the results from a new clinical study evaluating the efficacy of a hydroquinone skin care system (Nu-Derm®), plus tretinoin, in decreasing the severity of melasma, particularly in skin of color patients. This data was presented at the 22nd World Congress of Dermatology in May 2011. “The results of this study clearly demonstrate that the combination of a 4% hydroquinone skin care system and 0.025% tretinoin is highly effective in reducing the severity and pigmentation intensity of melasma in those with darker skin,” says Pearl Grimes, MD, co-lead investigator and Medical Director of the Vitiligo and Pigmentation Institute of Southern California. “Melasma is not merely a cosmetic nuisance, but a disorder that can cause emotional distress. I see it in my patients every day. I look forward to sharing this new information with my patients, as the treatment has also been shown to be well tolerated and to facilitate faster improvements in correcting photo-damaged skin.”